Ipsen faces yet another delay for rare disease drug in US

Less than a week before Ipsen's palovarotene was due to go in front of an FDA advisory committee, the meeting has been called off following a request by the regulator for more data.

After FDA setback, Ipsen gets first OK for rare disease drug...

After regulatory hold-ups in the US and Europe, Ipsen has claimed a confidence-boosting approval in Canada for palovarotene, a rare disease therapy acquired via its $1.3 billion takeover of

Ipsen hit by new palaver for rare disease drug palovarotene

Just as Ipsen's $1 billion bet on rare bone disease drug palovarotene seemed to be nearing the finish line, it has fallen at the final hurdle.

Ipsen craters as pricey rare disease drug is put on hold aga...

Hear from HealthTech Healx which raised $10m to accelerate d...

SMi Reports: AI HealthTech Company Healx, who raised $10m to advance drug dis

Orphan drugs: overcoming barriers to market access

What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.